Giulia Buzzatti
University of Genoa
21 Papers
18 Citations
Giulia Buzzatti is an academic researcher from University of Genoa. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
New emerging targets in cancer immunotherapy: the role of GITR.
Giulia Buzzatti,Chiara Dellepiane,Lucia Del Mastro +2 more
- 01 Jan 2019
TL;DR: Preclinical data on GITR-agonist monoclonal antibodies (mAbs) demonstrated antitumour activity in vitro and in vivo enhancing CD8+ and CD4+ effector T-cell activity and depleting tumour-infiltrating Tregs.
62
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
Mattia Garutti,Gaia Griguolo,Andrea Botticelli,Giulia Buzzatti,Carmine De Angelis,Lorenzo Gerratana,Chiara Molinelli,Vincenzo Adamo,Giampaolo Bianchini,Laura Biganzoli,Giuseppe Curigliano,Michelino De Laurentiis,Alessandra Fabi,Antonio Frassoldati,Alessandra Gennari,Caterina Marchiò,Francesco Perrone,Giuseppe Viale,Claudio Zamagni,Alberto Zambelli,Lucia Del Mastro,Sabino De Placido,Valentina Guarneri,Paolo Marchetti,Fabio Puglisi +24 more
TL;DR: The IRIDE (high risk definition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/her2−negative early breast cancer relapse, and may guide clinicians in the practical management of hormone- positive/HER2− negative early breast cancers.
Germline TP53 pathogenic variants and breast cancer: A narrative review.
Eva Blondeaux,Luca Arecco,Kevin Punie,Rossella Graffeo,Angela Toss,Carmine De Angelis,L. Trevisan,Giulia Buzzatti,Sabine C. Linn,Peter Dubsky,Mara Cruellas,Ann H. Partridge,Judith Balmaña,Shani Paluch-Shimon,Matteo Lambertini +14 more
TL;DR: A comprehensive overview of the criteria for offering tumor protein-53 testing, prevalence of TP53 carriers among patients with breast cancer, and what is known about its prognostic and therapeutic implications are provided in this article .
23
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
Eva Blondeaux,Matteo Lambertini,Andrea Michelotti,Benedetta Conte,Marco Benasso,Chiara Dellepiane,Claudia Bighin,S. Pastorino,Alessia Levaggi,Alessia D’ Alonzo,Francesca Poggio,Giulia Buzzatti,Chiara Molinelli,Piero Fregatti,Sergio Bertoglio,Francesco Boccardo,Lucia Del Mastro +16 more
TL;DR: In the MIG-1 trial as discussed by the authors, node-positive and high-risk node-negative breast cancer patients were randomised to receive six cycles of adjuvant fluorouracil, epirubicin and cyclophosphamide regimen administered every 3 or 2 weeks.
Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives.
Carlo Messina,Giulia Buzzatti,Chiara Dellepiane,Alessia Cavo,Francesco Tolomeo,Carlo Cattrini,Francesco Boccardo +6 more
TL;DR: The following review attempts to provide a comprehensive overview of the literature, focusing on new advances in targeted therapies for genitourinary tumours, as well as the promising results of the latest clinical trials and future perspectives.
11